Evidence map›Paper›PMID 41150202›Full record

ArticleToxins2025

RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity.

Ulf Ståhl, Emilia Lekholm, Emil Hamnevik, Robert Fredriksson, Sachin M Shridharani, Keywan Taghetchian, Joel L Cohen, Mark S Nestor, Åsa Liljegren Sundberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Therapeutic botulinum toxin preparations: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ulf StåhlGalderma, 752 28 Uppsala, Sweden.
Emilia LekholmGalderma, 752 28 Uppsala, Sweden.
Emil HamnevikGalderma, 752 28 Uppsala, Sweden.
Robert FredrikssonDepartment of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden.
Sachin M ShridharaniSchool of Medicine, Washington University, Saint Louis, MO 63110, USA.ORCID 0000-0002-0193-349X
Keywan TaghetchianSmoothline, 80331 Munich, Germany.ORCID 0009-0002-7929-5456
Joel L CohenAbout Skin Dermatology, Greenwood Village, CO 80111, USA.
Mark S NestorCenter for Clinical and Cosmetic Research, Aventura, FL 33180, USA.ORCID 0000-0002-8978-7932
Åsa Liljegren SundbergGalderma, 752 28 Uppsala, Sweden.

Funding

Galderma NA
6 · The paper itself

Abstract

Most botulinum toxin A (BoNT-A) products for esthetic use require reconstitution before administration. Ready-to-use relabotulinumtoxinA is a liquid manufactured using Precipitation-free Extraction and Activity-preserving, Refined Liquid (PEARL™) Technology from a proprietary

Indexed as

Botulinum Toxins, Type AAnimalsHumansMiceSynaptosomal-Associated Protein 25Botulinum Toxins, Type ASynaptosomal-Associated Protein 25biological activitybotulinum toxin type Aenzyme activityonabotulinumtoxinAready-to-userelabotulinumtoxinAspecific activity

Identifiers

PMID41150202
PMCPMC12567661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.